Literature DB >> 15609710

Five cases of anthracycline-induced cardiomyopathy effectively treated with carvedilol.

Yasushi Mukai1, Tomoki Yoshida, Ryuichi Nakaike, Naoko Mukai, Koji Iwato, Taiichi Kyo, Shunichi Kaseda.   

Abstract

Anthracycline, a widely used anti-cancer agent, can elicit irreversible cardiomyopathy called anthracycline-induced cardiomyopathy (ACM). In this report, we describe 5 cases of severe chronic heart failure due to ACM effectively treated with the beta-blocker, carvedilol. Their left ventricular function as well as cardiac symptoms were persistently improved after treatment with carvedilol, suggesting that carvedilol may be an effective therapeutic strategy for ACM as demonstrated in other forms of chronic heart failure.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15609710     DOI: 10.2169/internalmedicine.43.1087

Source DB:  PubMed          Journal:  Intern Med        ISSN: 0918-2918            Impact factor:   1.271


  5 in total

1.  Prevention and treatment of cardiomyopathy and heart failure in patients receiving cancer chemotherapy.

Authors:  Daniela Cardinale; Alessandro Colombo; Carlo Maria Cipolla
Journal:  Curr Treat Options Cardiovasc Med       Date:  2008-12

Review 2.  Cardio-oncology: Gaps in Knowledge, Goals, Advances, and Educational Efforts.

Authors:  Gina Biasillo; Carlo M Cipolla; Daniela Cardinale
Journal:  Curr Oncol Rep       Date:  2017-08       Impact factor: 5.075

3.  Role of β-blocker therapy in pediatric heart failure.

Authors:  Akash R Patel; Robert E Shaddy
Journal:  Ped Health       Date:  2010

Review 4.  Use of biomarkers for the assessment of chemotherapy-induced cardiac toxicity.

Authors:  Eric S Christenson; Theodore James; Vineet Agrawal; Ben H Park
Journal:  Clin Biochem       Date:  2014-11-07       Impact factor: 3.281

5.  Cardio-oncology: a new medical issue.

Authors:  D Cardinale; A Colombo; G Lamantia; N Colombo; M Civelli; G De Giacomi; C Pandini; M T Sandri; C M Cipolla
Journal:  Ecancermedicalscience       Date:  2008-12-15
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.